ProfileGDS5678 / 1417986_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 79% 81% 81% 81% 72% 72% 69% 69% 78% 82% 78% 79% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8769782
GSM967853U87-EV human glioblastoma xenograft - Control 25.580679
GSM967854U87-EV human glioblastoma xenograft - Control 35.7397281
GSM967855U87-EV human glioblastoma xenograft - Control 45.9674981
GSM967856U87-EV human glioblastoma xenograft - Control 55.8074481
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5147472
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5832172
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2410569
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.255469
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4596478
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9209182
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.4828478
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.5602779
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6580